Adverse Reactions, FDA and Patient Care - Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Adverse Reactions

FDA

Patient Care

FDA approves AbbVie-Genmab’s Epkinly to treat DLBCL

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab ‘s Epkinly (epcoritamab-bysp) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients. The FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients. “As

FDA

FDA Adverse Reactions Chemotherapy Patient Care

PharmDs – Crucial to Chronic Care Management Services: A Doctor’s Perspective

PharmD Live

JANUARY 25, 2022

According to the FDA, there are over 20,000 medications approved. In the physician’s office, when you put electronic health records (EHRs) with algorithms and artificial intelligence into the hands of your team pharmacist, you have an overwhelming opportunity to improve clinical benefits and even greater opportunity to improve patient care.

Adverse Reactions

Adverse Reactions Patient Care Communication Hospitals

FDA approves AbbVie-Genmab’s Epkinly to treat DLBCL

PharmDs – Crucial to Chronic Care Management Services: A Doctor’s Perspective

Stay Connected